MapLight Therapeutics, Inc. (MPLT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for MapLight Therapeutics, Inc. in 2026. The next earnings report is expected on September 2, 2026.
MapLight Therapeutics beat consensus estimates in its latest earnings report, with EPS of $-1.32 versus an estimate of $-1.3491 and revenue of $0 matching expectations. In the prior quarter EPS missed expectations while revenue also met estimates.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.